AVEO Pharmaceuticals, Inc.
AVEO
AVEO was delisted on the 19th of January, 2023.
73 hedge funds and large institutions have $31.9M invested in AVEO Pharmaceuticals, Inc. in 2019 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 17 increasing their positions, 21 reducing their positions, and 26 closing their positions.
70% more call options, than puts
Call options by funds: $3.1M | Put options by funds: $1.83M
12% less funds holding
Funds holding: 83 → 73 (-10)
15% less capital invested
Capital invested by funds: $37.3M → $31.9M (-$5.45M)
19% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 21
31% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$3.72M |
| 2 |
Millennium Management
New York
|
+$2.94M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.38M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$931K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$484K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$4.46M |
| 2 |
State Street
Boston,
Massachusetts
|
-$1.49M |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$409K |
| 4 |
Bank of New York Mellon
New York
|
-$263K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$249K |
AVEO Hedge Fund Activity: Q2 2019 in Review
73 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in AVEO Pharmaceuticals, Inc. (AVEO) for Q2 2019, worth a combined $31.9M — down 15% from $37.3M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of AVEO and 18 opened new positions — a net loss of 8 holders — while 21 trimmed existing stakes and 17 added.
The largest buyer was NEA Management Company, adding an estimated $3.72M. The largest seller was BlackRock, cutting an estimated $4.46M.
- 73 institutional investors held AVEO Pharmaceuticals, Inc. (AVEO) as of Q2 2019, down from 83 in Q1 2019.
- Funds reported $31.9M of AVEO Pharmaceuticals, Inc. stock for Q2 2019, down 15% quarter-over-quarter.
- 18 funds opened new AVEO Pharmaceuticals, Inc. positions in Q2 2019 and 26 closed out, a net change of -8 holders.
- The largest AVEO Pharmaceuticals, Inc. buyer in Q2 2019 was NEA Management Company, an estimated $3.72M added.
- The largest AVEO Pharmaceuticals, Inc. seller in Q2 2019 was BlackRock, an estimated $4.46M sold.
Based on aggregated 13F filings for Q2 2019.